PharVision Advisers’s Leggett & Platt LEG Stock Holding History

PharVision Advisers’s Portfolio LEG Stock Details LEG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-48,672	Closed	-$467K	–	407
2024 Q4	$467K	Buy	+48,672	New	+$583K	0.4%	51

Other funds holding LEG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

PharVision Advisers's LEG Position: Q1 2025 in Review

PharVision Advisers sold out of Leggett & Platt (LEG) in Q1 2025, closing a stake of 48,672 shares — an estimated $467K sold.

PharVision Advisers first reported a position in LEG in Q4 2024 and held it in 1 quarter. The position peaked at $467K in Q4 2024. 324 funds tracked by Wall St. Rank hold LEG as of Q1 2025.

PharVision Advisers reported no remaining Leggett & Platt position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 48,672 Leggett & Platt shares in Q1 2025, an estimated $467K.
PharVision Advisers first reported a position in Leggett & Platt in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Leggett & Platt position peaked at $467K in Q4 2024.
324 funds tracked by Wall St. Rank held Leggett & Platt as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.